13 rezultatov
FIELD OF THE INVENTION
The invention relates to the field of bacterial vaccine characterized to raise adequate immune responses in infants, children and adults against typhoid fever. Particularly, the present invention relates to conjugate vaccines and processes of manufacture thereof, wherein the
FIELD OF THE INVENTION
The invention relates to the field of bacterial vaccine characterized to raise adequate immune responses in infants, children and adults against typhoid fever. Particularly, the present invention relates to conjugate vaccines and processes of manufacture thereof, wherein the
BACKGROUND OF THE INVENTION
TF (typhoid fever) in man is the clinical manifestation of a generalized or systemic infection by Salmonella typhi, a gram-negative bacterium which penetrates the organism through the gastrointestinal tract, usually by ingestion of water or food contaminated by human
FIELD OF THE INVENTION
The present invention relates to immunoprophylaxis and vaccines. More particularly it relates to modifying a plant, fruit or synthetic polysaccharide such that it is immunogenic and may be used as a vaccine to prevent typhoid fever in infants and young children.
BACKGROUND OF
BACKGROUND OF THE INVENTION
1. Field of the Invention
All publications or patents mentioned in this specification are herein incorporated by reference.
This invention relates to a unique nucleic acid hybridization probe and method for the rapid detection of typhoid fever bacteria.
2. Prior
BACKGROUND OF THE INVENTION
Salmonella enterica serovar Typhi (S. typhi) and paratyphi (S. paratyphi), the causes of typhoid fever, results in more than 200,000 annual deaths (Parry et al., N. Engl. J. Med. 347:1770-1782; Crump et al., 2008, Antimicrob. Agents Chemother. 52:1278-1284; Raffatellu et
FIELD OF INVENTION
This invention relates to obtaining a biochemical vaccine against Salmonella fevers, typhoid and paratyphoid fevers.
BACKGROUND
The threat of an epidemic of Salmonella fevers is constant in the world as shown by epidemiological reports and the seriousness of the spread of
FIELD OF THE INVENTION
The present invention relates to attenuated Salmonella mutants which constitutively express the Vi antigen, as well as vaccines against typhoid fever containing the same, live vector vaccines containing the same, and DNA-mediated vaccines containing the same.
BACKGROUND OF THE
REFERENCE TO A SEQUENCE LISTING
The instant application contains a Sequence Listing, which is submitted in ASCII format via EFS-Web and is hereby incorporated by reference in its entirety. This ASCII copy, created on Jan. 4, 2018, is named 2602.0160001_SequenceListing_ST25.txt" and is 37,461,284
CROSS REFERENCE TO RELATED APPLICATIONS
This application is a national phase application under 35 U.S.C. .sctn. 371 of International Application No. PCT/IN2014/000530, filed on Aug. 19, 2014, which claims priority to Indian Patent Application No. 3750/CHE/2013, filed on Aug. 24, 2013; the
This application is a U.S. national phase application under 35 U.S.C. of .sctn. 371 of International Application No. PCT/IN2016/050218, filed Jul. 4, 2016, which claims priority of Indian Patent Application No. 3426/CHE/2015, filed Jul. 4, 2015, the disclosure of which is hereby incorporated by
The present invention relates in particular to a stabilized bivalent hepatitis A/typhoid fever (HA-Vi) immunization composition in which the Vi valence conserves its immunogenic power for at least 24 months approximately.
Hepatitis A and typhoid fever are two diseases for which a vaccine already
INTRODUCTION
This invention relates to a process for the production of a non-toxic B subunit of the heat-labile enterotoxin (LT-B) from a human isolate of an enterotoxigenic strain of Escherichia coli. This process utilizes recombinant DNA techniques, in which the requisite gene sequence is inserted